Search
etonogestrel (3-oxodesogestrel)
Indications:
- progestin used in progestin-only implant* (Implanon) & in combination with ethinyl estradiol in NuvaRing
* subdermal etonogestrel-releasing implants are the most effective contraceptives available [2]
Dosage:
- implant FDA-approved for 3 years, but effective for 5 years [2]
Pharmacokinetics:
1) metabolized by cyt P450 3A4
2) active metabolite of desogestrel
Adverse effects:
- unscheduled uterine bleeding
- ulipristal acetate 15 mg PO QD for 7 days of benefit [3]
General
progestational agent
Properties
Database Correlations
PUBCHEM cid=40976
References
- Prescriber's Letter 9(6):32 2002
- Bimla Schwarz E
The Etonogestrel-Releasing Contraceptive Implant:
Why Stop at 3 Years?
NEJM Journal Watch. Oct 20, 2016
Massachusetts Medical Society
(subscription needed) http://www.jwatch.org
- Ali M, Akin A, Bahamondes L et al.
Extended use up to 5 years of the etonogestrel-releasing
subdermal contraceptive implant: Comparison to levonorgestrel-
releasing subdermal implant.
Hum Reprod 2016 Sep 26
PMID: 27671673 Free Article
- Zigler RE, Madden T, Ashby C, Wan L, McNicholas C.
Ulipristal acetate for unscheduled bleeding in etonogestrel
implant users: A randomized controlled trial.
Obstet Gynecol. 2018 Oct;132(4):888-894. ePub Aug 17, 2018
PMID: 30130351
Component-of
estradiol/etonogestrel
ethinyl estradiol/etonogestrel
etonogestrel implant (Implanon)
NuvaRing (etonogestrel, ethinyl estradiol)